MedTrace Logo

A Real-life Study of the Use of Cabotegravir Plus Rilpivirine Long-acting in ART-experienced Pre-treated People With HIV

NCT06518408 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 287

Last updated 2024-07-24

No results posted yet for this study

Summary

The CABOTEGRAVIR Long Acting + RILPIVIRENE Long Acting regimen was currently endorsed by guidelines worldwide as an option for the Treatment of HIV-1 Infection, however collecting real-world data closer to clinical practice use is still necessary. This study also registers some immunological, metabolic,anti-inflammatory parameters and fat distribution analysis to observe a hypothetical improvement on these parameters.

Psychosocial aspects are also very important in these patients as these patients may suffer social stigma, and therefore suffer certain psychological disorders. Patient experience data will be assessed through PROs and bespoke single-item questions to collect patient perception of treatment and register psychosocial aspects related to their health status.

Conditions

  • Human Immunodeficiency Virus

Interventions

DRUG

Cabotegravir Injectable Product

long-acting regimen dosed every 2-months

DRUG

Rilpivirine Injectable Product

long-acting regimen dosed every 2-months

Sponsors & Collaborators

  • ViiV Healthcare

    collaborator INDUSTRY

  • University Hospital Virgen de las Nieves

    lead OTHER

Principal Investigators

  • CARMEN HIDALGO, PhD · HU Virgen de las Nieves

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2026-04-30
Completion
2027-09-30
FDA Drug
Yes

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06518408 on ClinicalTrials.gov